Compare ACR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACR | ACET |
|---|---|---|
| Founded | 2005 | 1947 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 77.3M |
| IPO Year | N/A | 2017 |
| Metric | ACR | ACET |
|---|---|---|
| Price | $19.50 | $8.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $24.50 | ★ $48.33 |
| AVG Volume (30 Days) | 16.3K | ★ 85.7K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.06 | $0.46 |
| 52 Week High | $24.61 | $9.05 |
| Indicator | ACR | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 55.45 |
| Support Level | $18.83 | $7.50 |
| Resistance Level | $21.27 | $8.68 |
| Average True Range (ATR) | 0.66 | 0.54 |
| MACD | -0.30 | -0.06 |
| Stochastic Oscillator | 6.52 | 64.64 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).